Terms: = Prostate cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Prognosis
168 results:
1. Functional Outcomes After Localized prostate cancer Treatment.
Al Hussein Al Awamlh B; Wallis CJD; Penson DF; Huang LC; Zhao Z; Conwill R; Talwar R; Morgans AK; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; O'Neil BB; Koyama T; Hoffman KE; Barocas DA
JAMA; 2024 Jan; 331(4):302-317. PubMed ID: 38261043
[TBL] [Abstract] [Full Text] [Related]
2. SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis.
Rajanala SH; Plym A; Vaselkiv JB; Ebot EM; Matsoukas K; Lin Z; Chakraborty G; Markt SC; Penney KL; Lee GM; Mucci LA; Kantoff PW; Stopsack KH
Carcinogenesis; 2024 Feb; 45(1-2):35-44. PubMed ID: 37856781
[TBL] [Abstract] [Full Text] [Related]
3. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.
Fettke H; Dai C; Kwan EM; Zheng T; Du P; Ng N; Bukczynska P; Docanto M; Kostos L; Foroughi S; Brown S; Graham LK; Mahon K; Horvath LG; Jia S; Kohli M; Azad AA
EBioMedicine; 2023 Sep; 95():104738. PubMed ID: 37549632
[TBL] [Abstract] [Full Text] [Related]
4. Serum Essential Elements and Survival after cancer Diagnosis.
Lubiński J; Lener MR; Marciniak W; Pietrzak S; Derkacz R; Cybulski C; Gronwald J; Dębniak T; Jakubowska A; Huzarski T; Matuszczak M; Pullella K; Sun P; Narod SA
Nutrients; 2023 Jun; 15(11):. PubMed ID: 37299574
[TBL] [Abstract] [Full Text] [Related]
5. Diabetes and prostate cancer Outcomes in Men with Nonmetastatic Castration-Resistant prostate cancer: Results from the SEARCH Cohort.
Sergeyev A; Gu L; De Hoedt AM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Klaassen Z; Terris MK; Guerrios-Rivera L; Freedland SJ; Csizmadi I
Cancer Epidemiol Biomarkers Prev; 2023 Sep; 32(9):1208-1216. PubMed ID: 37294698
[TBL] [Abstract] [Full Text] [Related]
6. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.
Sutera PA; Shetty AC; Hakansson A; Van der Eecken K; Song Y; Liu Y; Chang J; Fonteyne V; Mendes AA; Lumen N; Delrue L; Verbeke S; De Man K; Rana Z; Hodges T; Hamid A; Roberts N; Song DY; Pienta K; Ross AE; Feng F; Joniau S; Spratt D; Gillessen S; Attard G; James ND; Lotan T; Davicioni E; Sweeney C; Tran PT; Deek MP; Ost P
Ann Oncol; 2023 Jul; 34(7):605-614. PubMed ID: 37164128
[TBL] [Abstract] [Full Text] [Related]
7. ERG Status at the Margin Is Associated With Biochemical Recurrence After Radical prostatectomy With Positive Surgical Margins.
Salles DC; Mendes AA; Han M; Partin AW; Trock BJ; Jing Y; Lotan TL
Mod Pathol; 2023 Jul; 36(7):100147. PubMed ID: 36828362
[TBL] [Abstract] [Full Text] [Related]
8. Retrospective validation of bone risk stratification criteria for men with de novo metastatic hormone-naive prostate cancer in China.
Zhang Y; Ding L; Zheng Y; Wang K; Xia W; Wang J; Ge P
PeerJ; 2023; 11():e14500. PubMed ID: 36624752
[TBL] [Abstract] [Full Text] [Related]
9. Outcomes of Grade Group 2 and 3 prostate cancer on Initial Versus Confirmatory Biopsy: Implications for Active Surveillance.
Perera M; Jibara G; Tin AL; Haywood S; Sjoberg DD; Benfante NE; Carlsson SV; Eastham JA; Laudone V; Touijer KA; Fine S; Scardino PT; Vickers AJ; Ehdaie B
Eur Urol Focus; 2023 Jul; 9(4):662-668. PubMed ID: 36566100
[TBL] [Abstract] [Full Text] [Related]
10. Castration-resistant prostate cancer cells are dependent on the high activity of CDK7.
Pallasaho S; Gondane A; Kuivalainen A; Girmay S; Moestue S; Loda M; Itkonen HM
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5255-5263. PubMed ID: 36401094
[TBL] [Abstract] [Full Text] [Related]
11. The association between PI3K, JAK/STAT pathways with the PDL-1 expression in prostate cancer.
Kazan O; Kir G; Culpan M; Cecikoglu GE; Atis G; Yildirim A
Andrologia; 2022 Nov; 54(10):e14541. PubMed ID: 35880672
[TBL] [Abstract] [Full Text] [Related]
12. The prostate tissue-based telomere biomarker as a prognostic tool for metastasis and death from prostate cancer after prostatectomy.
Heaphy CM; Joshu CE; Barber JR; Davis C; Lu J; Zarinshenas R; Giovannucci E; Mucci LA; Stampfer MJ; Han M; De Marzo AM; Lotan TL; Platz EA; Meeker AK
J Pathol Clin Res; 2022 Sep; 8(5):481-491. PubMed ID: 35836303
[TBL] [Abstract] [Full Text] [Related]
13. Survival of cancer survivors with a new pancreatic cancer diagnosis.
Pruitt SL; Tavakkoli A; Zhu H; Heitjan DF; Gerber DE; Singal AG; Halm EA; Beg MS; Maddineni B; Kansagra AJ; Murphy CC
Cancer Med; 2023 Jan; 12(1):200-212. PubMed ID: 35674139
[TBL] [Abstract] [Full Text] [Related]
14. MRI-Detectability of Clinically Significant prostate cancer Relates to Oncologic Outcomes After prostatectomy.
Wibmer AG; Lefkowitz RA; Lakhman Y; Chaim J; Nikolovski I; Sala E; Fine SW; Donahue TF; Kattan MW; Hricak H; Vargas HA
Clin Genitourin Cancer; 2022 Aug; 20(4):319-325. PubMed ID: 35618599
[TBL] [Abstract] [Full Text] [Related]
15. Genomic landscape of microsatellite instability in Chinese tumors: A comparison of Chinese and TCGA cohorts.
Li Z; Jia Y; Zhu H; Yuan H; Xing X; Xin Y; Ma T; Pang F; Zhang Y; Hu Y; Jia S; Ji J
Int J Cancer; 2022 Oct; 151(8):1382-1393. PubMed ID: 35567574
[TBL] [Abstract] [Full Text] [Related]
16. Methylation Subtypes of Primary prostate cancer Predict Poor prognosis.
Wang X; Jordahl KM; Zhu C; Livingstone J; Rhie SK; Wright JL; Grady WM; Boutros PC; Stanford JL; Dai JY
Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1473-1482. PubMed ID: 35437583
[TBL] [Abstract] [Full Text] [Related]
17. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
Chen Y; Zheng X; Lin J; Gao X; Xiong J; Liu J; Fei Z; Chen C
Oral Oncol; 2022 May; 128():105860. PubMed ID: 35428026
[TBL] [Abstract] [Full Text] [Related]
18. Radiomics-based prognosis classification for high-risk prostate cancer treated with radiotherapy.
Franzese C; Cozzi L; Badalamenti M; Baldaccini D; D'Agostino G; Fogliata A; Navarria P; Franceschini D; Comito T; Clerici E; Reggiori G; Tomatis S; Scorsetti M
Strahlenther Onkol; 2022 Aug; 198(8):710-718. PubMed ID: 35059760
[TBL] [Abstract] [Full Text] [Related]
19. Types of second primary cancer influence overall survival in cutaneous melanoma.
Zheng G; Chattopadhyay S; Sundquist K; Sundquist J; Försti A; Hemminki A; Hemminki K
BMC Cancer; 2021 Oct; 21(1):1123. PubMed ID: 34663263
[TBL] [Abstract] [Full Text] [Related]
20. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase.
Lin HM; Mak B; Yeung N; Huynh K; Meikle TG; Mellett NA; Kwan EM; Fettke H; Tran B; Davis ID; Mahon KL; Zhang A; Stockler MR; Briscoe K; Marx G; Crumbaker M; Stricker PD; Du P; Yu J; Jia S; Scheinberg T; Fitzpatrick M; Bonnitcha P; Sullivan DR; Joshua AM; Azad AA; Butler LM; Meikle PJ; Horvath LG
EBioMedicine; 2021 Oct; 72():103625. PubMed ID: 34656931
[TBL] [Abstract] [Full Text] [Related]
[Next]
